# US 2025/0145609 A1 · 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145609 A1
- Document ID: US20250145609A1
- Status: Published application
- Kind: A1
- Application number: 18/835,518
- Filed: 2023-02-09
- Published: 2025-05-08
- Earliest claimed: 2022-02-09
- Applicants: Aurigene Oncology Limited
- Inventors: Chandrasekhar ABBINENI; Susanta SAMAJDAR; Sanjita SASMAL; Bilash KUILA; Subhendu MUKHERJEE; Suraj TATYASAHEB GORE
- Web page: https://patentgrep.com/patent/US20250145609A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides 3-substituted pyridazine compound of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof;
wherein,
A represents 5- to 6-membered heteroarylenyl or 6-membered arylenyl; wherein the arylenyl and heteroarylenyl are unsubstituted or substituted with 1, 2 or 3 Ra;
Ra, at each occurrence, independently represents hydroxy, hydroxyalkyl, halogen, alkoxy, alkyl, haloalkyl or cyano;
R1 is halogen, alkyl, haloalkyl, alkoxy, hydroxy, hydroxyalkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from oxo, hydroxy, alkoxy, halogen, alkyl, haloalkyl, amino and cyano;
R2 is hydrogen, hydroxy, hydroxyalkyl, halogen, alkoxy, alkyl, amino, aminoalkyl, haloalkyl or cyano;
Q is amino, aminoalkyl, hydroxy, hydroxyalkyl, halogen, alkoxy, alkyl, haloalkyl or cyano;
L is a bond, —N(Rx)—(CRxRy)p-O—, —O—(CRxRy)p-, —O—(CRxRy)p-O—, —C≡C—(CRxRy)p-, -heterocycloalkylenyl-heterocycloalkylenyl-, -heterocycloalkylenyl-O—, -heterocycloalkylenyl-C≡C—, —C≡C-heterocycloalkylenyl-, —O-heterocycloalkylenyl-(CRxRy)p-, —N(Rx)-heterocycloalkylenyl-(CRxRy)p-, -cycloalkylenyl-(CRxRy)p-, -heteroarylenyl-(CRxRy)p-, -heterocycloalkylenyl-(CRxRy)p-, -heterocycloalkylenyl-(CRxRy)p1-heterocycloalkylenyl- or -heterocycloalkylenyl-O-heterocycloalkylenyl-; wherein the cycloalkylenyl, heteroarylenyl and heterocycloalkylenyl are unsubstituted or substituted with 1, 2 or 3 Rd; and the left side of L group is attached to A and right side of L group is attached to M;
Rd, at each occurrence, is independently selected from hydroxy, halogen, alkyl and alkoxy; or any two Rd groups attached with the same C atom together form an oxo group;
Rx and Ry, at each occurrence, are independently selected from hydrogen and alkyl;
M is selected from M-1 and M-2:
wherein
Z is 5- to 6-membered heteroarylenyl or 5- to 6-membered heterocycloalkylenyl; wherein the heteroarylenyl and heterocycloalkylenyl groups are unsubstituted or substituted with oxo, hydroxy, halogen, alkyl or alkoxy;
R3 and R8 independently represents alkyl, haloalkyl or hydroxyalkyl;
R4 and R9 independently represents hydrogen, alkyl, haloalkyl or hydroxyalkyl;
R5, R6, R10 and R11 are independently selected from hydrogen, alkyl, halogen, heteroalkyl, haloalkyl, hydroxyalkyl and acyl;
R7 and R12 independently represents thiazolyl which is unsubstituted or substituted with alkyl, hydroxy, amino or haloalkyl;
‘p’ is an integer selected from 0, 1, 2, 3, 4, 5 and 6; and
‘p1’ is an integer selected from 1, 2, 3 and 4.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is halogen, alkyl, haloalkyl, alkoxy, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from oxo, hydroxy, alkoxy, halogen, alkyl, haloalkyl, amino and cyano.

### Claim 3 (depends on 1, 2)

The compound of any one of claims 1 to 2, wherein R1 is methoxy, chloro, trifluoromethyl, phenyl or pyridinyl; wherein the phenyl and pyridinyl are unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from oxo, hydroxy, methoxy, fluoro, chloro, difluoromethyl and trifluoromethyl.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1 to 3, wherein R2 is hydrogen.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1 to 4, wherein A represents phenylenyl which is unsubstituted or substituted with 1 or 2 Ra.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1 to 5, wherein A represents 5- to 6-membered heteroarylenyl which is unsubstituted or substituted with 1 or 2 Ra.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1 to 6, wherein A represents phenylenyl, furanylenyl, thienylenyl, pyrrolylenyl, pyrazolylenyl, imidazolylenyl, oxazolylenyl, isoxazolylenyl, thiazolylenyl, isothiazolylenyl, 1H-tetrazolylenyl, oxadiazolylenyl, triazolylenyl, pyridylenyl, pyrimidinylenyl, pyrazinylenyl, pyridazinylenyl, 1,2,3-triazinylenyl, 1,2,4-triazinylenyl or 1,3,5-triazinylenyl; wherein each group is unsubstituted or substituted with 1 or 2 substituent(s) independently selected from hydroxy, hydroxyalkyl, halogen, alkoxy, alkyl, haloalkyl and cyano.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1 to 7, wherein Q represents amino or alkoxy.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1 to 8, wherein L is a bond.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1 to 9, wherein L is —N(Rx)—(CRxRy)p-O—, —O—(CRxRy)p-, —O—(CRxRy)p-O— or —C≡C—(CRxRy)p-.

### Claim 11 (depends on 10)

The compound of claim 10, wherein L is —N(CH3)—CH2CH2—O—, —N(CH3)—CH2CH2CH2-0-, —N(CH3)—CH2CH2CH2CH2—O—, —NH—CH2CH2—O—, —NH—CH2CH2CH2—O—, —O—CH2—, —O—CH2CH2—, —O—CH2CH2CH2—, —O—CH2CH2—O—, —O—CH2CH2CH2CH2—, —C≡C—CH2—, —C≡C—CH2CH2— or —C≡C—CH2CH2CH2—.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1 to 11, wherein L is -heterocycloalkylenyl-heterocycloalkylenyl-, -heterocycloalkylenyl-O—, -heterocycloalkylenyl-C≡C—, —C≡C-heterocycloalkylenyl-, —O-heterocycloalkylenyl-(CRxRy)p-, —N(Rx)-heterocycloalkylenyl-(CRxRy)p-, -cycloalkylenyl-(CRxRy)p-, -heteroarylenyl-(CRxRy)p-, -heterocycloalkylenyl-(CRxRy)p-, -heterocycloalkylenyl-(CRxRy)p1-heterocycloalkylenyl- or -heterocycloalkylenyl-O-heterocycloalkylenyl-.

### Claim 13 (depends on 12)

The compound of claim 12, wherein the heterocycloalkylenyl is azetidinylenyl, pyrrolidinylenyl, piperidinylenyl, piperazinylenyl, tetrahydropyranyl, tetrahydropyridazinylenyl, morpholinylenyl, thiomorpholinylenyl, 1,4-dioxanylenyl, dioxidothiomorpholinylenyl, oxapiperazinylenyl, oxapiperidinylenyl, tetrahydropyranylenyl, dihydropyranylenyl or dihydropyrimidinylenyl; wherein each group is unsubstituted or substituted with 1 or 2 Rd.

### Claim 14 (depends on 12)

The compound of claim 12, wherein the cycloalkylenyl is cyclopropylenyl, cyclobutylenyl, cyclopentylenyl, cyclohexylenyl or cycloheptylenyl.

### Claim 15 (depends on 9, 10, 11, 12, 13, 14)

The compound of any one of claims 9 to 14, wherein L is —N(CH3)—CH2CH2—O—, —N(CH3)—CH2CH2CH2—O—, —N(CH3)—CH2CH2CH2CH2—O—, —NH—CH2CH2—O—, —NH—CH2CH2CH2—O—, —O—CH2—, —O—CH2CH2—, —O—CH2CH2CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd.

### Claim 16 (depends on 1)

The compound of claim 1, wherein M is represented by the formula M-1;
wherein
R3 represents alkyl, haloalkyl or hydroxyalkyl;
R4 represents hydrogen, alkyl, haloalkyl or hydroxyalkyl;
R5 and R6 are independently selected from hydrogen, alkyl, halogen, haloalkyl and hydroxyalkyl; and
R7 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 17 (depends on 16)

The compound of claim 16, wherein M-1 is represented by formula M-1A or M-1B:

### Claim 18 (depends on 16, 17)

The compound of anyone claims 16 to 17, wherein M-1 is selected from:
wherein, R4 represents hydrogen; and R6 represents alkyl.

### Claim 19 (depends on 1)

The compound of claim 1, wherein M is reperesented by formula M-2;
wherein,
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R8 represents alkyl, heteroalkyl, haloalkyl or hydroxyalkyl;
R9 represents hydrogen, alkyl, haloalkyl or hydroxyalkyl;
R10 and R11 are independently selected from hydrogen, alkyl, halogen, heteroalkyl, haloalkyl and hydroxyalkyl; and
R12 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 20 (depends on 19)

The compound of claim 19, wherein M-2 is represented by formula M-2A or M-2B:

### Claim 21 (depends on 19, 20)

The compound of any one of claims 19-20, wherein M-2 is represented by formula:
wherein, R8 represents alkyl; R11 represents hydrogen or alkyl; and
R12 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 22 (depends on 19, 20, 21)

The compound of any one of claims 19-21, wherein M-2 is

### Claim 23 (depends on 1)

The compound of claim 1, represented by compound of formula (IA):

### Claim 24 (depends on 23)

The compound of claim 23, wherein Q is selected from amino and alkoxy.

### Claim 25 (depends on 23, 24)

The compound of claim 23 or 24, wherein R1 is halogen, alkyl, haloalkyl, alkoxy, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1 or 2 substituent(s) independently selected from oxo, hydroxy, alkoxy, halogen and haloalkyl.

### Claim 26 (depends on 23, 24, 25)

The compound of any one of claim 23 to 25, wherein R2 is hydrogen.

### Claim 27 (depends on 23, 24, 25, 26)

The compound of any one of claim 23 to 26, wherein Ra, at each occurrence, independently represents halogen.

### Claim 28 (depends on 23, 24, 25, 26, 27)

The compound of any one of claims 23 to 27, wherein
L is a bond, —N(CH3)—CH2CH2—O—, —NH—CH2CH2—O—, —O—CH2—, —O—CH2—CH2—O—, —O—CH2CH2CH2CH2—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd.

### Claim 29 (depends on 23, 24, 25, 26, 27, 28)

The compound of any one of claims 23 to 28, wherein
M is selected from M-1 and M-2;
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R3 and R8 independently represents alkyl;
R4 and R9 independently represents hydrogen or alkyl;
R5, R6, R10 and R11 are independently selected from hydrogen and alkyl; and
R7 and R12 independently represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 23 to 29, wherein
Ra, at each occurrence, independently represents halogen;
R1 is halogen, haloalkyl, alkoxy, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1 or 2 substituent(s) independently selected from oxo, hydroxy, alkoxy, halogen and haloalkyl;
R2 is hydrogen;
Q is amino or alkoxy;
L is a bond, —O—CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd;
Rd, at each occurrence, is independently selected from alkyl, hydroxy and halogen; or
any two Rd groups attached with the same C atom together form an oxo group;
M is selected from M-1 and M-2;
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R3 and R8 independently represents alkyl;
R4 and R9 independently represents hydrogen;
R5, R6, R10 and R11 are independently selected from hydrogen and alkyl; and
R7 and R12 independently represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 31 (depends on 1)

The compound of claim 1, represented by compound of formula (IB):

### Claim 32 (depends on 31)

The compound of claim 31, wherein Ra, at each occurrence, independently represents halogen.

### Claim 33 (depends on 31, 32)

The compound of any one of claims 31 to 32, wherein
L is a bond, —O—CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd.

### Claim 34 (depends on 31, 32, 33)

The compound of any one of claim 31 to 33, wherein M is selected from M-1 and M-2; wherein
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R3 and R8 independently represents alkyl;
R4 and R9 independently represents hydrogen or alkyl;
R5, R6, R10 and R11 are independently selected from hydrogen and alkyl; and
R7 and R12 independently represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 35 (depends on 31, 32, 33, 34)

The compound of any one of claims 31 to 34, wherein
Ra at each occurrence, independently represents halogen;
R1 is halogen, haloalkyl, alkoxy, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1 or 2 substituent(s) independently selected from hydroxy, alkoxy, halogen and haloalkyl;
L is a bond, —O—CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd;
Rd, at each occurrence, is independently selected from alkyl, hydroxy and halogen; or
any two Rd groups attached with the same C atom together form an oxo group;
M is selected from M-1 and M-2;
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R3 and R8 independently represents alkyl;
R4 and R9 independently represents hydrogen;
R5, R6, R10 and R11 are independently selected from hydrogen and alkyl; and
R7 and R12 independently represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 36 (depends on 1)

The compound of claim 1, represented by compound of formula (IC):

### Claim 37 (depends on 36)

The compound of claim 36, wherein Ra represents halogen.

### Claim 38 (depends on 36, 37)

The compound of claim 36 or 37, wherein L is a bond, —O—CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd.

### Claim 39 (depends on 36)

The compound of claim 36, wherein
R3 represents alkyl;
R6 is selected from hydrogen and alkyl; and
R7 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 40 (depends on 36, 37, 38, 39)

The compound of any one of claims 36 to 39, wherein
R1 is halogen, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1 or 2 substituent(s) independently selected from hydroxy, alkoxy, halogen and haloalkyl;
Ra represents alkyl;
L is a bond, —O—CH2—, —O—CH2CH2CH2CH2—, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—, —C≡C—CH2—, —C≡C—CH2CH2—, —C≡C—CH2CH2CH2—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd;
Rd, at each occurrence, selected from alkyl, hydroxy and halogen; or any two Rd groups attached with the same C atom together form an oxo group;
R3 represents alkyl;
R6 is selected from hydrogen and alkyl; and
R7 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 41 (depends on 1)

The compound of claim 1, represented by compound of formula (ID):

### Claim 42 (depends on 41)

The compound of claim 41, wherein
L is a bond, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd;
Rd, at each occurrence, is independently selected from alkyl, hydroxy and halogen; or
any two Rd groups attached with the same C atom together form an oxo group.

### Claim 43 (depends on 41, 42)

The compound of claim 41 or 42, wherein
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R8 represents alkyl;
R11 is selected from hydrogen and alkyl; and
R12 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 44 (depends on 41, 42, 43)

The compound of any one of claims 41 to 43, wherein
R1 is halogen, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the aryl and heteroaryl groups are unsubstituted or substituted with 1 or 2 substituent(s) independently selected from hydroxy, alkoxy, halogen and haloalkyl;
L is a bond, —O—CH2CH2—O—, —NH—CH2CH2—O—, —N(CH3)—CH2CH2—O—,
wherein each ring is unsubstituted or substituted with 1 or 2 Rd;
Rd, at each occurrence, is independently selected from alkyl, hydroxy and halogen; or
any two Rd groups attached with the same C atom together form an oxo group;
Z is oxazolylenyl, pyrazolylenyl, isoxazolylenyl or piperidinylenyl;
R8 represents alkyl;
R11 is selected from hydrogen and alkyl; and
R12 represents thiazolyl which is unsubstituted or substituted with alkyl or haloalkyl.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound of any one of claims 1 to 44, is selected from:
Compound
Structure
1
2
3
4
5
Isomer-1 of compound 4;
6
Isomer-2 of compound 4;
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Isomer-1 of compound 32;
34
Isomer-2 of compound 32;
35
36
Isomer-1 of compound 35;
37
Isomer-2 of compound 35;
38
39
40
41
Isomer-1 of compound 40;
42
Isomer-2 of compound 40;
43
44
Isomer-1 of compound 43;
45
Isomer-2 of compound 43;
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
and
70
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A pharmaceutical composition comprising the compound of any one of claims 1 to 45 or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof and a pharmaceutically acceptable carrier or an excipient.

### Claim 47 (depends on 46)

The pharmaceutical composition of claim 46, for use in degrading a target protein in a subject, wherein the target protein is SMARCA2 and/or SMARCA4.

### Claim 48 (depends on 47)

The pharmaceutical composition for use of claim 47, wherein the subject is afflicted with a disease or disorder dependent upon at least one of SMARCA2 and SMARCA4.

### Claim 49 (depends on 47, 48)

The pharmaceutical composition for use of claim 47 or 48, wherein the disease or disorder is cancer selected from hematologic cancers, lung cancer (i.e. non-small cell lung cancer), acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, head and neck cancer, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, liver cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's; Burkitt's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, malignant rhabdoid tumor (MRT), rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer or Wilms' tumor.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A compound according to any one of claims 1 to 45, or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof for use as a medicament.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for degrading a target protein in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound according to any one of claims 1 to 45 or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein the target protein is SMARCA2 and/or SMARCA4.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for treating a disease or disorder dependent upon at least one of SMARCA2 and SMARCA4 in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 45 or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the disease or disorder dependent upon SMARCA2 and/or SMARCA4 is cancer selected from hematologic cancers, lung cancer (i.e. non-small cell lung cancer), acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, head and neck cancer, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, liver cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's; Burkitt's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, malignant rhabdoid tumor (MRT), rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer or Wilms' tumor.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A compound according to any one of claims 1 to 45 for use in the treatment of a disease or disorder dependent upon SMARCA2 and/or SMARCA4.

### Claim 56 (depends on 55)

The compound for use according to claim 55, wherein the disease or disorder dependent upon SMARCA2 and/or SMARCA4 is cancer.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

Use of a compound or a pharmaceutical acceptable salt or a stereoisomer or a tautomer thereof according to any one of claims 1 to 45, in the manufacture of a medicament for the treatment of a disease or disorder dependent upon SMARCA2 and/or SMARCA4; wherein the disease or disorder is cancer.
